10 September 2021

Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:

“Lung cancer patients today received welcome news of interim access to a new treatment, Sotorasib, following licensing thanks to Amgen working together with NHS England to achieve this.

“Triple negative incurable secondary breast cancer patients are desperately concerned that drug company Gilead won’t follow suit and guarantee all eligible patients free-of-charge access to a promising treatment, Trodelvy, following its licensing. Trodelvy could potentially bring them precious extra time with loved ones.

“If Gilead fails to do this, hundreds of women who face short prognoses and limited treatment options could have an agonising wait of up to eight months until a decision about routine use of Trodelvy on the NHS is made – a wait that, tragically, means access to Trodelvy will come too late for many women.

“Almost 200,000 people have already signed our petition calling on Gilead to do the right thing. We are calling on Gilead to agree an interim access scheme with NHS England and provide Trodelvy free-of-charge on the NHS to all eligible patients once the drug is licensed; unless this happens, women will pay the ultimate, heartbreaking price of being denied the precious chance of more time to live.”